Patients using Accolade, Proponent, Essentio, Altrua 2 Standard Life and Altrua 2 Extended Life pacemakers, as well as Visionist and Valitude cardiac resynchronization therapy pacemakers, may need to have their devices replaced earlier than anticipated, according to the FDA’s Dec. 16 alert.
Two deaths have been reported in association with these devices, according to Boston Scientific.
The FDA recommends providers monitor patients using these pacemakers. If a patient exhibits symptoms that suggest the device may have initiated safety mode, surgery should be scheduled to replace the device.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
